Abstract Hypertensive disorders represent major causes of pregnancy-related maternal mortality worldwide. Similar to the non-pregnant population, hypertension is the most common medical disorder encountered during pregnancy and is estimated to occur in about 6-8 % of pregnancies. A recent report highlighted hypertensive disorders as one of the major causes of pregnancy-related maternal deaths in the USA, accounting for 579 (12.3 %) of the 4,693 maternal deaths that occurred between 1998 and 2005. In low-income and middle-income countries, preeclampsia and its convulsive form, eclampsia, are associated with 10-15 % of direct maternal deaths. The optimal timing and choice of therapy for hypertensive pregnancy disorders involves carefully weighing the risk-versus-benefit ratio for each individual patient, with an overall goal of improving maternal and fetal outcomes. In this review, we have compared and contrasted the recommendations from different treatment guidelines and outlined some newer perspectives on management. We aim to provide a clinically oriented guide to the drug treatment of hypertension in pregnancy.
Introduction
Hypertension in pregnancy includes a range of conditions, most notably preeclampsia, a form of hypertension unique to pregnancy that occurs de novo or may be superimposed on chronic hypertension. The other forms, chronic and gestational hypertension, usually have more benign courses [1] . Preeclampsia, a pregnancy-specific disorder characterized by hypertension (C140/90 mmHg) and proteinuria (C300 mg in a 24-h urine), affects 3-4 % of all pregnancies worldwide. However, recent obstetric literature questions the importance of kidney injury (as demonstrated by proteinuria) in the diagnosis of preeclampsia, suggesting that a subclass of ''non-proteinuric preeclampsia'' should be added [2] or that detection of proteinuria should not be mandatory for a preeclampsia diagnosis [3] . Risk factors include primiparity, previous preeclampsia, increased maternal body mass index (BMI) before pregnancy, ethnicity (Black women are more at risk), multiple gestations, and underlying medical conditions, such as renal disease and diabetes mellitus [4] . Preeclampsia is a condition that involves numerous and constant interactions among the placental, immunologic, and cardiovascular systems [5] . It is a syndrome associated with impaired early placentation and dysfunctional trophoblast development, defective placental angiogenesis, and an exaggerated maternal systemic inflammatory response [6] [7] [8] [9] . Risks to the fetus include premature delivery, growth retardation, and death. Treatment of severe hypertension is necessary to prevent cerebrovascular, cardiac, and renal complications in the mother.
In the US, the National High Blood Pressure Education Program (NHBPEP) Working Group Report on High Blood Pressure in Pregnancy was first presented in 1990 and most recently updated in 2000 [1] . The definition and treatment recommendations for hypertension in pregnancy, unlike those for hypertension in the general population, have not similarly evolved and vary among different organizations that provide guidance in this area. Blood pressure (BP) levels requiring therapy in pregnancy, although somewhat different among various groups and professional societies, have been set, in general, at higher systolic and diastolic levels than for the general population [10] . There are several reasons for this. First, there was (and still is) a relative paucity of well designed clinical trials establishing the benefit of treatment of mild chronic hypertension during pregnancy, typically defined in the relevant literature as a systolic BP (SBP) 140-160 mmHg and/or diastolic BP (DBP) 90-100 mmHg. As a result, the current treatment approach is based on the assumption that hypertension of 4-5 months duration in a young woman without other risk factors does not increase her risk for cardiovascular disease, neither during the pregnancy nor later in life. However, there is increasing evidence that hypertension in pregnancy is an under-recognized risk factor for future cardiovascular disease (CVD). Compared with women who have had normotensive pregnancies, those who are hypertensive during pregnancy are at greater risk of cardiovascular and cerebrovascular events years after their pregnancies [11] [12] [13] .
There is the concern that decreased BP in the mother may compromise uteroplacental unit perfusion and fetal circulation. With respect to antihypertensive therapy, the choice has been limited to those that have proven to be relatively safe, have long been in clinical use, and have a side-effect profile that most obstetricians have found to be acceptable [10] .
Throughout the article, where available, we have ranked the level of evidence in support for the measurement and treatment of hypertension in pregnancy. A full explanation of the ranking systems used is available in the appendices.
Measuring Blood Pressure (BP) in Pregnancy
The guidelines for measuring BP in pregnancy are outlined in Table 1 . Throughout this paper we refer to BP levels that are based on clinic blood pressure measurements. There has been much discussion on using ambulatory BP monitoring (ABPM) in pregnancy, but international guidelines currently base diagnosis and treatment interventions on clinic measurements.
Classification of Hypertension in Pregnancy and Treatment Guidelines
According to NHBPEP and The American College of Obstetricians and Gynecologists (ACOG) practice bulletins, hypertension in pregnancy is classified as chronic hypertension, preeclampsia-eclampsia, preeclampsia superimposed upon chronic hypertension, and gestational hypertension [1, 14, 15] . Chronic hypertension is defined as BP C140/90 mmHg before pregnancy or \20th week of gestation or use of antihypertensive medication before pregnancy. Preeclampsia-eclampsia is a pregnancy-specific disorder that occurs after 20 weeks gestation. Eclampsia is the convulsive form of preeclampsia and affects 0.1 % of all pregnancies. Preeclampsia can also occur superimposed upon chronic hypertension. Gestational hypertension is defined as new-onset BP C140 mmHg systolic or 90 mmHg diastolic on at least two occasions, at least 6 h apart, after 20 weeks gestation, in the absence of proteinuria. This category encompasses women with preeclampsia who have not yet developed proteinuria, those with transient hypertension, if BP returns to normal by 12 weeks postpartum, and women with chronic hypertension, if BP elevation persists after 12 weeks.
The NHBPEP guidelines state that, in pregnancy, a normal or acceptable BP is a SBP B140 and DBP B90 mmHg, mild hypertension a SBP 140-150 or DBP 90-109 mmHg and severe hypertension a BP C160 systolic or C110 diastolic mmHg [1] .
NHBPEP advises that antihypertensive medication might be safely withheld in women with a history of chronic hypertension, and recommend restarting treatment at [150-160 mmHg SBP and/or 100-110 mmHg DBP, or in the presence of left ventricular hypertrophy (LVH) or renal insufficiency [1] . In preeclampsia, antihypertensive therapy can be withheld unless there is a persistent DBP 105-110 mmHg or higher (III-C). ACOG Practice Bulletins recommend that antihypertensive therapy be used for women with a history of chronic hypertension who develop severe hypertension in pregnancy, for maternal benefit, and that treatment of uncomplicated mild hypertension is not beneficial [14, 15] .
The ACOG recently convened a task force on hypertension in pregnancy and have provided an up-to-date statement with recommendations on treatment of hypertension in pregnancy [16] . They recommend that for women with mild gestational hypertension or preeclampsia (SBP \160 mmHg or DBP \110 mmHg), antihypertensives are not recommended (the quality of this evidence is moderate and the strength of this recommendation is qualified). For women with preeclampsia and a sustained SBP C160 mmHg or DBP C110 mmHg, antihypertensive therapy is recommended (the quality of this evidence is moderate and the strength of this recommendation is strong). In pregnant women with chronic hypertension and no end-organ damage, no antihypertensive therapy is needed if the SBP \160 mmHg or DBP \105 mmHg (the quality of this evidence is low and the strength of this recommendation is qualified). In pregnant women with chronic hypertension who are on antihypertensive therapy, the BP should be maintained between 120/80 mmHg and 160/105 mmHg (the quality of this evidence is low and the strength of this recommendation is qualified). 24-h ABPM -Useful for the evaluation of early hypertension (\20 weeks gestation), where one-third of women will have 'white coat' hypertension and half of these women will go on to have ABPM confirmed hypertension later in pregnancy ABPM less useful for screening for 'white coat' hypertension in second half of pregnancy ESH on ABPM [65] ABPM particularly useful for detecting white-coat and nocturnal hypertension in pregnancy White-coat hypertension has a more favorable outcome than sustained hypertension diagnosed by ABPM Nocturnal hypertension is higher in women with preeclampsia than in those with gestational hypertension, and is associated with more maternal and fetal complications
The predictive accuracy of ABPM remains low; ambulatory pulse pressure and daytime DBP have been shown to be predictive of birth weight
The abbreviations/key codes in parentheses represent the ranking of evidence and grading of recommendations used by the SOGC, by NHBPEP Working Group Report on High Blood Pressure and ACOG. An explanation of these can be found in the appendices Other international societies and organizations have different definitions and levels at which therapy should be initiated and these are also presented in Table 2 . These recommendations come from the Society of Obstetricians and Gynaecologists of Canada (SOGC), the European Society of Hypertension/European Society of Cardiology (ESH/ESC), the UK National Institute for Health and Care Excellence (NICE), and the Society of Obstetric Medicine of Australia and New Zealand (SOMANZ).
Drug treatment of Hypertension in Pregnancy
According to the NHBPEP, methyldopa, labetalol, betablockers (other than atenolol), slow-release nifedipine, and a diuretic in pre-existing hypertension are considered as appropriate treatment [1] . If a woman's BP is well controlled on an agent pre-pregnancy, she may continue it during pregnancy, with the exception of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). If restarting drug therapy in women with chronic hypertension, methyldopa is recommended as first-line therapy. For emergency treatment in preeclampsia, intravenous hydralazine, labetalol, and oral nifedipine can be used [1] . The ACOG Practice Bulletins also recommend that methyldopa and labetalol are appropriate first-line agents, and that beta-blockers and ACE inhibitors are not recommended [14, 15] .
In current practice, antihypertensive medications other than methyldopa and hydralazine are being used more often in pregnancy (Table 3) , and particularly in patients Table 2 Guidelines for diagnosis and treatment of hypertensive disorders of pregnancy (adapted from Moser et al. [68] ) SOGC [31] ESH/ESC [42, 66] NICE [43] SOMANZ [30] Definitions of HTN in pregnancy A. Pre-existing HTN (before pregnancy or \20 weeks)
(1) with co morbid conditions (2) for whom BP control cannot be achieved with these agents, or in the presence of intolerable side effects. The drug treatments for severe acute hypertension in preeclampsia are highlighted in Fig. 1 [1] . Severe hypertension in preeclampsia being defined as a BP C160 mmHg systolic, C105 mmHg diastolic, or both.
Profiles of Recommended Drug Therapies

Centrally Acting a 2 -Adrenergic Agonists
Methyldopa is a centrally acting a 2 -adrenergic receptor agonist. It inhibits vasoconstriction via a central mechanism by reducing catecholamine release [17] . It decreases central sympathetic outflow, decreasing systemic vascular resistance without decreasing cardiac output [18] . The side effects of methyldopa include fatigue, depression, poor sleep, and decreased salivation. Dose-independent adverse effects include elevated liver enzymes in up to 5 % of women, and some patients can develop a positive antinuclear antigen or antiglobulin (Coombs') test, although a clinical hemolytic anemia is rare [18, 19] . It has been suggested that methyldopa should be avoided in women with a prior history of depression, because of the possible increased risk of postnatal depression [20] . Methyldopa has a long history of use in pregnancy and does not appear teratogenic [18] . Methyldopa has a record of safety in pregnancy, as established by follow-up studies in the 1980s of children exposed to the drug in utero [21] . More recent studies indicate that, in hypertensive pregnancy disorders, treatment with methyldopa does not affect the maternal uterine artery Doppler pulsatility and resistance indices, suggesting that it does not impair uteroplacental circulation and consequent fetal growth [22] . The doses of methyldopa recommended in pregnancy are similar to those used in non-pregnant patients [23] .
Clonidine is a centrally acting adrenergic agonist. It works as an antihypertensive agent by stimulating a-2 adrenergic receptors in the brainstem, thereby decreasing central adrenergic output [24] . It acts on both peripheral and central a 2 -adrenergic receptors to decrease the cardiac output, systemic vascular resistance, SBP, and heart rate [25] . Clonidine is similar to methyldopa with respect to safety and efficacy [25] . It is used generally as a third-line agent for multidrug control of refractory hypertension [19] .
According to the US FDA, methyldopa is a Class B drug and clonidine is a Class C drug. According to either the World Health Organization (WHO) and/or Thomson lactation ratings, methyldopa is usually compatible with breast milk and clonidine has possible breast-milk effects. 
Peripherally Acting Adrenergic-Receptor Antagonists
Labetalol, a non-selective b-blocking agent with vascular a 1 -receptor-blocking capabilities is widely used in pregnancy [26] . Fetal growth restriction and low placental weight in patients (with essential hypertension) have been associated with the use of atenolol during the second trimester [27] , but not with other b-blocking agents, such as labetalol (an a-and b-blocker), which is used frequently for the treatment of severe acute hypertension during pregnancy, and has shown equivalent efficacy and better tolerability than hydralazine [28] . Side effects, including fatigue, lethargy, exercise intolerance, sleep disturbance, and bronchoconstriction, have been reported [26] . bblockers are not associated with teratogenicity [26] . In a review of antihypertensive drug therapy for mild-tomoderate hypertension during pregnancy, b-blockers appear to be more effective than methyldopa in limiting episodes of severe hypertension in women with hypertensive disorders of pregnancy [29] . However, at the same time, this review showed no evidence of a difference in the risks of preeclampsia, neonatal death, preterm birth, or small-for-gestational-age (SGA) babies.
Prazosin is an a 1 -blocker that selectively blocks postsynaptic a 1 -adrenoceptors, producing a decrease in total peripheral resistance (and a reflex increase in sympathetic tone) [18] . It is considered as a second-line agent by SO-MANZ [30] , but is not recommended by SOGC [31] . Prazosin has a useful role in chronic renal disease complicating pregnancy. It is associated with postural hypotension and palpitations.
Fetal growth restriction and low placental weight in patients (with essential hypertension) have been associated with the use of atenolol during the second trimester [27] , but not with other b-blocking agents, such as labetalol (an a-and b-blocker), which is used frequently for the treatment of severe acute hypertension during pregnancy, and has shown equivalent efficacy and better tolerability than hydralazine [28] . The benefits and concerns of antihypertensive agents are outlined in Table 2 .
According to the FDA, labetalol is a Class C drug. It may be associated with a risk of fetal bradycardia and neonatal hypoglycemia. According to either the WHO and/or Thomson lactation ratings, methyldopa is usually compatible with breast milk. Atenolol is an FDA Class D drug. It is not recommended due to risk of intrauterine growth restriction (IUGR) and is not recommended if breast feeding.
Calcium Channel Blockers
Oral nifedipine and verapamil are frequently seen as secondline agents used for the treatment of hypertension in pregnancy. They do not appear to be teratogenic [32] . Calcium channel blockers (CCBs) inhibit the influx of calcium ions to vascular smooth muscle, resulting in arterial vasodilation; nifedipine acts predominantly on the vasculature and verapamil acts primarily on the heart [18, 17] . Side effects of CCB use in the mother include tachycardia, palpitations, peripheral edema, headaches, and facial flushing [33] .
According to the FDA, nifedipine and verapamil are Class C drugs. With all CCBs, there is a risk of interactions with magnesium, resulting in profound hypotension. Nifedipine and verapamil are usually compatible with breast feeding.
Direct Vasodilators
Hydralazine is now predominantly used intravenously for the treatment of severe hypertension in pregnancy. Hydralazine selectively relaxes arteriolar smooth muscle. Adverse effects include headache, nausea, flushing, and palpitations. It does not appear teratogenic. There have been reports of neonatal thrombocytopenia, rare cases of a pyridoxine-responsive polyneuropathy with chronic use, and drug-induced lupus [34] .
However, there is evidence that intravenous labetalol or oral nifedipine are preferable first-line agents compared with intravenous hydralazine in severe hypertension in pregnancy [28] .
Sodium nitroprusside is rarely used in pregnancy and is reserved for life-threatening severe hypertension [35] . Adverse effects include cyanide and thiocyanate toxicity, and also the risk of cardio-neurogenic syncope.
Hydralazine is an FDA Class C drug. It is usually compatible with breast feeding.
Diuretics
The use of diuretic therapy during pregnancy remains controversial, primarily due to theoretical concerns about reduced plasma volume. In a randomized trial of women with chronic hypertension in pregnancy, the use of diuretics reduced plasma volume, but was not associated with adverse pregnancy outcomes [36] . Women on maintenance diuretic therapy prior to pregnancy can be continued on this regimen, unless they develop premonitory signs of preeclampsia, such as proteinuria. At that point, some physicians would opt to stop diuretic medications, due to the concern that, with the lower plasma volume characteristic of preeclampsia, the use of diuretics may further aggravate the hypovolemic state, stimulate the renin-angiotensin system, and worsen hypertension [37] . However, the 2000 NHBPEP Working Group Report recognized that the major concern for the use of diuretics in pregnancy is primarily theoretical, as supporting evidence for their deleterious effects is lacking.
Thiazides are FDA Class B drugs. They may cause volume contraction and electrolyte abnormalities, but this is rare with small doses. Diuretics may reduce milk production [19] . Spironolactone is not recommended due to potential fetal antiandrogen effects.
5.6 Renin-Angiotensin System Drugs ACE inhibitors and ARBs are contraindicated in pregnancy due to their association with adverse fetal effects [38] . ACE inhibitors are labeled FDA class C for the first trimester of pregnancy, and FDA class D for the second and third trimesters.
Current Clinical Practice
As discussed in earlier sections, there are several guidelines and recommendations available to practitioners treating hypertension in pregnancy. However, these may not always reflect clinical practice. Two recent reviews give us an indication of actual drug therapy being used in hypertension in pregnancy. Table 4 summarizes drug therapy currently being used in clinical practice to treat very high blood pressure in pregnancy.
There is further evidence of the increasing use of antihypertensives in pregnancy. A review of outpatient antihypertensive medication use during pregnancy in a Medicaid population was performed from 2000 to 2006 [39] . It noted that the prevalence of antihypertensive use, both in the first trimester and in pregnancy overall, increased during this period by approximately 50 %; by the end, nearly 5 % of all pregnancies were exposed to antihypertensive therapy [39] . The authors reported significant variation in the range of antihypertensive drugs used across all trimesters of pregnancy and in the approach to the management of patients entering pregnancy on antihypertensive medication. There were study limitations, but a significant number of women taking antihypertensives prior to pregnancy were kept on their same drug and not switched to one of the preferred agents. b-blockers, thiazides, and CCBs were often used as first-line agents.
Drugs Used for the Prevention of Preeclampsia/ Eclampsia
Magnesium Sulphate and Other Anticonvulsants for Preeclampsia
In a Cochrane review of treatment of women with preeclampsia, magnesium sulphate more than halves the risk of eclampsia, and probably reduces maternal death [40] . In women with eclampsia, magnesium sulphate reduces the risk ratio of maternal death and of recurrence of seizures, compared with diazepam.
Antiplatelet Agents and Preeclampsia
A review of 59 trials, involving 37,560 women, found that low doses of aspirin reduced the risk of preeclampsia by 17 %, the risk of fetal or neonatal deaths by 14 %, and the relative risk of preterm births by 8 % [41] . Doses of up to 75 mg appear to be safe. Guidelines from the ESH/ESC suggest that women at high risk of preeclampsia (from hypertension in a previous pregnancy, chronic kidney disease, autoimmune disease, such as systemic lupus erythematosus, or antiphospholipid syndrome, type 1 or 2 diabetes mellitus, or chronic hypertension), or with more than one moderate risk factor for preeclampsia (first pregnancy, age [40 years, pregnancy interval of [10 years, BMI [35 kg/m 2 at first visit, family history of preeclampsia, and multiple gestations, e.g. twins), may be advised to take 75 mg of aspirin daily from 12 weeks until the birth of the baby, provided that they are at low risk of gastrointestinal hemorrhage [42] . Similarly, the UK NICE guidelines advise women to take aspirin 75 mg/day from 12 weeks until birth, if they have at least two moderate risk factors (as listed above), or if at least one high-risk factor (as listed above) for preeclampsia exists [43] . They state that this is an unlicensed indication and that informed consent should be obtained. There is support for the use of lowdose aspirin before 16 weeks, with investigators suggesting the possibility that because the transformation of uterine spiral arteries by trophoblasts is normally completed by 16-20 weeks, and this is abnormal in preeclampsia, early use of aspirin may be beneficial [44, 45] .
Antioxidants for Preventing Preeclampsia
It has been demonstrated that supplementation with vitamin C (at a dose of 1,000 mg daily) and vitamin E (at a dose of 400 IU daily) does not reduce the rates of either serious adverse outcomes of pregnancy-associated hypertension or preeclampsia among low-risk, nulliparous women [46] .
Calcium Supplementation for Preventing Hypertensive Disorders
A review of calcium supplementation during pregnancy for preventing hypertensive disorders concluded that calcium supplementation appears to approximately halve the risk of preeclampsia, reduce the risk of preterm birth, and the rare occurrence of the composite outcome 'death or serious morbidity' [47] . Of note, most of the women in these trials had a low calcium diet and were supplemented with at least 1 g of calcium daily. However, the evidence for added calcium for the prevention of hypertensive disorders is conflicting [48] .
Other Agents
Fish oil supplementation and vitamin and nutrient supplements appear to have no benefit in the prevention of hypertensive disorders [49] . Other management options, such as the use of corticosteroids, plasma volume expansion, or interventions, such as rest or exercise, have not been validated [50] . Steroid therapy is recommended only for lung maturation [30, 31, 43] . Currently, several interventional trials for hypertension in pregnancy are in progress, including the Control of Hypertension in Pregnancy Study trial [51] , with further information on these trials being available at ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform. Results from these trials may further enhance our treatment therapies for hypertension in pregnancy.
Novel Therapeutic Targets and Emerging Treatments
Angiogenesis
Dysregulation of angiogenesis appears to play a key role in the pathogenesis of preeclampsia. Placental cystathionine c-lyse (CSE) expression is reduced in preeclampsia, leading to reduced plasma levels of the pro-angiogenic gaseous vasodilator, hydrogen sulfide (H 2 S), and increased sFlt-1 [52] . Targeting CSE/H 2 S activity may be a potential therapy pending additional studies.
Aminopeptidases
Aminopeptidases, such as placental leucine aminopeptidase (P-LAP) and aminopeptidase A (APA), do not cross the placental barrier. In the pregnant, spontaneously hypertensive rat, APA acts as an antihypertensive agent, degrading vasoactive peptides, and as a result, normalizes BP [53] . The role of aminopeptidases as potential therapeutic agents is being investigated.
Heme Oxygenase 1
A recent study examined heme oxygenase (HO)-1 induction in a rat model of placental ischemia. George et al. [54] suggest two potential pathways through which HO-1 acts, namely, normalization of angiogenic balance in the placenta, and reduction in oxidative stress. Both pathways are potential targets for treatment in preeclampsia.
Marinobufagenin
Uddin et al. [55] , and others, have investigated the role of marinobufagenin (MBG), a cardiotonic steroid, and its antagonist, resibufogenin (RBG), in experimental animal models of preeclampsia. This group has demonstrated that in a rat model of preeclampsia, MBG inhibits first trimester cytotrophoblast cell function and that urinary excretion of MBG is elevated prior to the development of hypertension and proteinuria. MBG also causes hypoxia and ischemia, leading to an imbalance of pro-and antiangiogenic factors. RBG, when given early in pregnancy, prevented the development of hypertension, proteinuria, and IUGR.
G Protein-Coupled Receptor Targets
There is potential for investigation of novel G ProteinCoupled Receptor (GPCR)-based therapies in preeclampsia, including calcitonin receptor-like receptor/receptor activitymodifying protein 1 complexes, the angiotensin AT1, 2 and Mas receptors, and the relaxin receptor RXFP1 [56] .
Inhibitors of the Enzyme Poly ADP Ribose Polymerase
In states of increased oxidative stress, such as diabetes, overstimulation of poly ADP ribose polymerase (PARP) leads to endothelial dysfunction, and PARP inhibitors have been shown to be of benefit [57] . A recent investigation has demonstrated a protective effect of a PARP inhibitor, preventing the development of both endothelial dysfunction and hypertension, in a rat model of preeclampsia [57] .
Gasotransmitters
Nitric oxide, a potent vasodilator that mediates endothelium-dependent relaxation, has been linked to endothelial dysfunction in preeclampsia [58] . Carbon monoxide (CO), nitric oxide, and hydrogen sulphide are endogenously generated gaseous transmitters known as gasotransmitters.
In preclinical animal models, the therapeutic use of CO gas and CO-releasing molecules demonstrated anti-inflammatory properties and cardiovascular protective effects [59] . These gaseous molecules may have a potential role in the therapeutics for several diseases, including CVD and preeclampsia, although their instability and potential toxicity are significant drawbacks.
Podocytes
Derangements of podocytes and podocyte-specific proteins are implicated in preeclampsia. There is evidence of an association between dysregulated pro-angiogenic factors, hypertension, and podocyte injury. Further investigation focusing on the mechanism of podocyte injury and detachment may identify novel therapeutic targets. These are only a few of the more recent potential therapeutic targets under investigation.
Perspectives in Management
Over the last decade, new evidence has emerged, both with respect to the pathophysiology of preeclampsia and the benefits of early hypertension treatment in the general population, which may affect the management of hypertensive pregnant patients. The notion that pregnant women with chronic hypertension are at low risk for cardiovascular complications within the short duration of pregnancy may be in question given the current trend towards advanced maternal age at first pregnancy. These women may have other cardiovascular risk factors, such as obesity or hyperlipidemia, and/or signs of target organ hypertensive damage. In addition, modern methods of assisted reproduction (such as in vitro fertilization) have enabled women with CVD risk factors that are associated with decreased fertility (such as diabetes mellitus and renal disease) to conceive. In these women, treatment of hypertension of even a short duration may improve their cardiovascular risks, especially in view of recent studies in the general population showing an important correlation between the time taken to achieve goal BP and clinical outcomes, namely better outcomes with earlier and more effective treatment [60, 61] . Finally, recent studies have indicated that cerebrovascular events in women with severe preeclampsia and eclampsia may occur when the SBP exceeds 150 mmHg, and called for a paradigm shift, by recommending antihypertensive therapy when the SBP reaches or exceeds 155-160 mmHg [62] . Indeed, most investigators agree that antihypertensive therapy in the peripartum period should be initiated when the DBP approaches 100 mmHg, or for a BP C150/100 mmHg [63] . As abrupt decreases in BP may adversely affect uteroplacental perfusion, treatment of hypertension mandates close maternal and fetal monitoring as the BP is lowered. The ultimate therapeutic goal is to prevent maternal complications without compromising fetal wellbeing.
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Appendices
Appendix 1: The NHBPEP Working Group Report on High Blood Pressure in Pregnancy reviewed and classified studies providing evidence supporting their recommendations. They used the following explanatory symbols and appended them to some of their references and to some of their citations [1] M: Meta-analysis; an analysis of a compendium of experimental studies Ra: Randomized controlled studies Re: Retrospective analyses; case-control studies 
